Charles Schwab Investment Management Inc. acquired a new stake in CeriBell (NASDAQ:CBLL - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 96,582 shares of the company's stock, valued at approximately $2,500,000. Charles Schwab Investment Management Inc. owned about 0.27% of CeriBell as of its most recent filing with the SEC.
Separately, Rhumbline Advisers bought a new stake in shares of CeriBell during the fourth quarter valued at approximately $320,000.
CeriBell Price Performance
Shares of CBLL traded up $0.47 on Wednesday, reaching $19.24. 115,360 shares of the company's stock were exchanged, compared to its average volume of 240,524. The stock's 50 day simple moving average is $22.13. CeriBell has a 12 month low of $18.50 and a 12 month high of $32.75.
CeriBell (NASDAQ:CBLL - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to the consensus estimate of $17.55 million. As a group, analysts expect that CeriBell will post -2.46 EPS for the current year.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on CBLL shares. TD Cowen boosted their price objective on shares of CeriBell from $31.00 to $36.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. Canaccord Genuity Group reissued a "buy" rating and issued a $33.00 target price on shares of CeriBell in a research note on Wednesday, February 26th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $32.60.
View Our Latest Report on CBLL
About CeriBell
(
Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Articles
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
